(Press-News.org) DURHAM, N.C. – A new cancer treatment that links chemotherapy with an agent that homes in on specific breast cancer cells was significantly better than the current drug regimen at keeping patients' advanced tumors from progressing, according to results from a Phase III clinical trial led by Kimberly Blackwell, M.D., of the Duke Cancer Institute.
Participants with invasive breast cancer who took the investigational drug, called trastuzumab emtansine, or T-DM1, also had fewer and less harsh side effects than study participants who received a standard treatment.
The findings were reported Sunday at the American Society of Clinical Oncology annual meeting in Chicago, and will form the basis for Genentech, the drug's manufacturer, to seek marketing approval from the U.S. Food and Drug Administration. Genentech and its parent company, Roche, funded the clinical trial.
"This drug is significantly better than the current approved combination in keeping the cancer under control," said Blackwell, director of the Breast Cancer Clinical Program at Duke and principal investigator of the international study. "This is a drug that brings us another step closer to treating cancer without the side effects of chemotherapy. It's going to be a good option for patients faced with HER-2 positive tumors."
Nearly 1,000 people with advanced breast cancer were enrolled during the three-year study. All the participants had a form of aggressive breast cancer distinguished by elevated levels of a protein known as human epidermal growth factor receptor 2, or HER-2. The protein promotes the growth of cancer cells, and plays a role in about 20 percent of invasive breast cancers.
For many people with HER-2 positive breast cancers, an antibody called trastuzumab has been an effective treatment, binding to the HER-2 protein on the surface of cancer cells and interfering with its ability to fuel tumor growth. Trastuzumab is prescribed alone or as an added treatment along with chemotherapy drugs.
T-DM1 represents one of the first in a new class of cancer-fighting agents called antibody drug conjugates. Linking the antibody trastuzumab directly with chemotherapy, the conjugate works like a sort of smart bomb, homing in on the HER-2 targets in the tumor cells and delivering the added payload of chemotherapy.
Blackwell and colleagues report that the median amount of time people on T-DM1 had no cancer growth was 9.6 months, compared to a median 6.4 months for people receiving the current standard drug regimen of capecitabine and lapatinib.
"These are significant and clinically meaningful improvements against comparative drugs that are highly effective for this group of patients," Blackwell said.
After two years, 65.4 percent of the T-DM1 patients were alive, compared to 47.5 percent of participants on standard treatment. The difference, while a notable trend, failed to meet a statistical benchmark set by its predetermined study design. A later analysis of overall survival is planned.
The new drug also caused fewer side effects. Blackwell said trastuzumab emtansine caused liver injury and a drop in blood platelets in some study participants, but most did not suffer the hair loss, rashes, nausea and diarrhea common to traditional chemotherapies.
"This is a more targeted way of delivering chemotherapy to HER-2 overexpressed cells," Blackwell said. "It delivers the drug directly to the cancer cells, while avoiding cells that don't really need to receive chemotherapy, which keeps patients from getting sick."
As a result, more people were able to stay on the drug without dose reductions, with 16.3 percent of participants on T-DM1 needing to adjust the dosage, compared to 53.4 percent of participants on capecitabine and 27.3 percent for lapatinib.
"As a clinician who takes care of breast cancer patients, it's important to have a treatment that is both effective and well tolerated," Blackwell said. "This drug has very little dose-limiting toxicity. That is in stark contrast to so many of the treatments we have available today. This drug works."
INFORMATION:
New breast cancer drug halts tumor growth better than standard therapy
2012-06-05
ELSE PRESS RELEASES FROM THIS DATE:
'Most comprehensive' genetic analysis of maize plant will help raise yields, expand its range
2012-06-05
Cold Spring Harbor, NY and Washington, DC – An international research team involving 17 institutions including Cold Spring Harbor Laboratory has published the most comprehensive analysis to date of the maize genome. It is an achievement that substantially increases scientists' understanding of differences across related but different species of the plant, which most North Americans call corn, as well as the nature of differences found within individual maize species.
The research is expected to speed development of improved varieties of corn, which is one of the ...
New hope for migraine sufferers
2012-06-05
New hope has arrived for migraine sufferers following a Griffith University study with the people of Norfolk Island.
Led by Professor Lyn Griffiths from the University's Griffith Health Institute,
the team has identified a new region on the X chromosome as playing a role in migraine.
The research provides compelling evidence for a new migraine susceptibility gene involved in migraine. The study also indicated that there may be more than one X chromosomal gene involved and implicated a gene involved in iron regulation in the brain.
All females have two X chromosomes ...
Greening operating rooms benefit the bottom line and the environment
2012-06-05
Efforts to "green" operating rooms can result in cost savings for hospitals and reduce the environmental impact without compromising patient care, argues an analysis published in CMAJ (Canadian Medical Association Journal).
"The operating room is a disproportionate contributor to health care waste and represents a high-yield target for change," writes Dr. Yoan Kagoma, Schulich School of Medicine & Dentistry, Western University, London, Ontario, with coauthors.
Operating rooms produce approximately 20%-33% of all waste in hospitals, and much of this waste is subjected ...
Acetaminophen overdoses in children can be life-threatening but are avoidable
2012-06-05
Acetaminophen, a widely available over-the-counter medication, can cause liver toxicity in children if doses are exceeded, and more public education is needed to warn of potential adverse effects, states an article published in CMAJ (Canadian Medical Association Journal).
"Acetaminophen overdose is a major cause of acute liver failure and is the most common identifiable cause of acute liver failure in children," writes Dr. Rod Lim, Department of Pediatrics, Children's Hospital, London Health Sciences Centre, London, Ontario, with coauthors. "Repeated supratherapeutic ...
Canada should ban off-label antibiotic use in agriculture
2012-06-05
Canada should ban off-label use of antibiotics in farm animals because it contributes significantly to antibiotic resistance in humans, states an editorial in CMAJ (Canadian Medical Association Journal).
Off-label use means using antibiotics for purposes other than those indicated on the label.
"Of greatest concern is the promotion of resistance to antibiotics that may currently represent the last resort for treating some highly resistant infections in humans," writes Barbara Sibbald, Deputy Editor, CMAJ.
Other countries and regions are far ahead of Canada in limiting ...
Food for thought? Study says soy may not help preserve thinking skills in women
2012-06-05
MINNEAPOLIS – Contrary to earlier reports, a new study suggests that soy protein may not preserve overall thinking abilities in women over the age of 45, but may improve memory related to facial recognition. The study is published in the June 5, 2012, print issue of Neurology®, the medical journal of the American Academy of Neurology.
"Soy is a staple of many traditional Asian diets and has been thought possibly to improve cognition in postmenopausal women," said study author Victor W. Henderson, MD, MS, with Stanford University in Palo Alto, Calif., and a Fellow with ...
How infectious disease may have shaped human origins
2012-06-05
Roughly 100,000 years ago, human evolution reached a mysterious bottleneck: Our ancestors had been reduced to perhaps five to ten thousand individuals living in Africa. In time, "behaviorally modern" humans would emerge from this population, expanding dramatically in both number and range, and replacing all other co-existing evolutionary cousins, such as the Neanderthals.
The cause of the bottleneck remains unsolved, with proposed answers ranging from gene mutations to cultural developments like language to climate-altering events, among them a massive volcanic eruption. ...
Scientists identify mechanism for regulating plant oil production
2012-06-05
UPTON, NY - Scientists at the U.S. Department of Energy's Brookhaven National Laboratory have identified key elements in the biochemical mechanism plants use to limit the production of fatty acids. The results suggest ways scientists might target those biochemical pathways to increase the production of plant oils as a renewable resource for biofuels and industrial processes.
"Now that we understand how this system operates - how plants 'know' when they've made enough oil and how they slow down production - we can look for ways to break the feedback loop so they keep making ...
Reign of the giant insects ended with the evolution of birds
2012-06-05
SANTA CRUZ, CA--Giant insects ruled the prehistoric skies during periods when Earth's atmosphere was rich in oxygen. Then came the birds. After the evolution of birds about 150 million years ago, insects got smaller despite rising oxygen levels, according to a new study by scientists at the University of California, Santa Cruz.
Insects reached their biggest sizes about 300 million years ago during the late Carboniferous and early Permian periods. This was the reign of the predatory griffinflies, giant dragonfly-like insects with wingspans of up to 28 inches (70 centimeters). ...
Mayo Clinic IDs immune system glitch tied to fourfold higher likelihood of death
2012-06-05
ROCHESTER, Minn. -- Mayo Clinic researchers have identified an immune system deficiency whose presence shows someone is up to four times likelier to die than a person without it. The glitch involves an antibody molecule called a free light chain; people whose immune systems produce too much of the molecule are far more likely to die of a life-threatening illness such as cancer, diabetes and cardiac and respiratory disease than those whose bodies make normal levels. The study is published in the June issue of Mayo Clinic Proceedings.
Researchers studied blood samples ...